Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0124


Challenges and expectations for novel biologics discovery in HER2-negative breast cancer

Franco Roviello, M.D.

Affiliation: Professor Franco Roviello, Via A. De Gasperi, 5-53100 Siena, Italy

E-mail :



Since there is no abstract available we provide the first paragraph .

Approximately half a century after the discovery of the human epidermal growth factor (hEG F) and its receptor type 2 (HER2), biologically targeted agents such as trastuzumab and lapatinib may improve oncological outcomes of breast cancer patients whose tumors cancer cells overexpress HER2. The HER2 status has been a standard prognostic factor and patients with breast cancer are classified into HER2-negative and HER2-positive disease. Although prognosis of patients with HER2-positive cancer, as compared to HER2-negative is poorer, the addition of the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor small molecule lapatinib may alter this poor outcome [1-4].



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 6 March 2010